UNIVERSITE DE STRASBOURG;INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);INSTITUT HOSPITALIER UNIVERSITAIRE DE STRASBOURG;ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
发明人:
Thomas BAUMERT,Yujin HOSHIDA
申请号：
US15568959
公开号：
US20180119096A1
申请日:
2016.04.28
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.
